Dynorphin-A and vasopressin release in the rat: a structure-activity study

Area of Science:

• Neuroendocrinology
• Peptide signaling
• Hormone regulation

Background:

• Vasopressin (VP) is crucial for fluid balance and blood pressure.
• Dynorphin-A peptides are endogenous opioid peptides with diverse physiological roles.
• The precise mechanisms of dynorphin-A's influence on VP release are not fully elucidated.

Purpose of the Study:

• To investigate the in vivo and in vitro effects of specific dynorphin-A fragments and antisera on vasopressin release.
• To determine the differential roles of dynorphin-A fragments in central and peripheral VP regulation.

Main Methods:

• Intracerebroventricular (i.c.v.) injections of dynorphin-A fragments and antisera in vivo.
• In vitro studies using isolated neural lobes to assess electrically evoked VP release.
• Administration of an endopeptidase inhibitor to evaluate dynorphin-A-(1-8) activity.

Main Results:

• In vivo, dynorphin-A-(1-17) was most potent in inhibiting VP release, followed by dynorphin-A-(1-13) and dynorphin-A-(1-8).
• Dynorphin-A-(1-17) antiserum enhanced VP release centrally, while dynorphin-A-(1-13) antiserum elevated plasma VP levels.
• In vitro, dynorphin-A-(1-8) suppressed VP release from the posterior pituitary, but other fragments and antisera had no effect.

Conclusions:

• Dynorphin-A-(1-17) plays a significant role in the central control of neurohypophysial VP release.
• Dynorphin-A-(1-8) is involved in the peripheral control of VP release within the posterior pituitary.
• The intermediate fragment dynorphin-A-(1-13) appears to influence VP release at both central and peripheral levels.